Literature DB >> 10204638

Cell-associated infectious HIV-1 viral load as a predictor of clinical progression and survival among HIV-1 infected injection drug users and homosexual men.

C M Lyles1, N M Graham, J Astemborski, D Vlahov, J B Margolick, A J Saah, H Farzadegan.   

Abstract

Cell-associated infectious HIV-1 viral load was measured using semi-quantitative microculture techniques to determine its predictive capability for progression to AIDS or survival among HIV-1 infected injecting drug users (IDU) and homosexual men (HM). The authors followed 296 IDU and 240 HM from February 1992 through September 1995 for: (i) death, (ii) AIDS, and (iii) AIDS or bacterial infection. At baseline, viral load was quantified using microculture techniques to determine infectious units per million peripheral blood mononuclear cells (IUPM). Data were analyzed using standard statistical methods for survival analysis. Of the 536 total participants, 106 died (20%), and 98 of the 481 AIDS-free participants developed AIDS (20%). The relative hazard of AIDS for a viral load of > or = 100 IUPM, relative to a negative culture (0 IUPM), was 6.73 (95% CI: 2.23-20.3) after adjusting for risk group, initial CD4+ count, and other covariates. The adjusted relative hazard of death for a viral load of > or = 100 IUPM vs. 0 IUPM was 2.57 (95% CI: 0.97 6.80). Viral load predicted time to death within the < 200 cells/ul CD4+ stratum. The predictive value of viral load on HIV-1 progression did not vary by risk group. These data show that cell associated infectious HIV-1 viral load was significantly predictive of progression across risk groups for AIDS and death among those severely immune compromised.

Entities:  

Mesh:

Year:  1999        PMID: 10204638     DOI: 10.1023/a:1007556327269

Source DB:  PubMed          Journal:  Eur J Epidemiol        ISSN: 0393-2990            Impact factor:   8.082


  33 in total

1.  Comparison of lymphocyte immunophenotypes obtained simultaneously from two different data acquisition and analysis systems on the same flow cytometer.

Authors:  J B Margolick; E R Scott; K R Chadwick; H M Shapiro; A D Hetzel; S J Smith; R F Vogt
Journal:  Cytometry       Date:  1992

2.  Prognostic indicators for development of AIDS among intravenous drug users.

Authors:  A Muñoz; D Vlahov; L Solomon; J B Margolick; J C Bareta; S Cohn; J Astemborski; K E Nelson
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1992

3.  Longitudinal analysis of quantitative virologic measures in human immunodeficiency virus-infected subjects with > or = 400 CD4 lymphocytes: implications for applying measurements to individual patients. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.

Authors:  W B Paxton; R W Coombs; M J McElrath; M C Keefer; J Hughes; F Sinangil; D Chernoff; L Demeter; B Williams; L Corey
Journal:  J Infect Dis       Date:  1997-02       Impact factor: 5.226

4.  Differences in progression to AIDS between injection drug users and homosexual men with documented dates of seroconversion.

Authors:  I J Spijkerman; M W Langendam; P J Veugelers; E J van Ameijden; I P Keet; R B Geskus; A van den Hoek; R A Coutinho
Journal:  Epidemiology       Date:  1996-11       Impact factor: 4.822

5.  Variability and prognostic values of virologic and CD4 cell measures in human immunodeficiency virus type 1-infected patients with 200-500 CD4 cells/mm(3) (ACTG 175). AIDS Clinical Trials Group Protocol 175 Team.

Authors:  J L Lathey; M D Hughes; S A Fiscus; T Pi; J B Jackson; S Rasheed; T Elbeik; R Reichman; A Japour; R T D'Aquila; W Scott; B P Griffith; S M Hammer; D A Katzenstein
Journal:  J Infect Dis       Date:  1998-03       Impact factor: 5.226

6.  Clinical manifestations and predictors of disease progression in drug users with human immunodeficiency virus infection.

Authors:  P A Selwyn; P Alcabes; D Hartel; D Buono; E E Schoenbaum; R S Klein; K Davenny; G H Friedland
Journal:  N Engl J Med       Date:  1992-12-10       Impact factor: 91.245

7.  Effect of sex, age and transmission category on the progression to AIDS and survival of zidovudine-treated symptomatic patients.

Authors:  S Vella; M Giuliano; M Floridia; A Chiesi; C Tomino; A Seeber; S Barcherini; R Bucciardini; S Mariotti
Journal:  AIDS       Date:  1995-01       Impact factor: 4.177

8.  Changes in survival after acquired immunodeficiency syndrome (AIDS): 1984-1991.

Authors:  L P Jacobson; A J Kirby; S Polk; J P Phair; D R Besley; A J Saah; L A Kingsley; L K Schrager
Journal:  Am J Epidemiol       Date:  1993-12-01       Impact factor: 4.897

9.  Survival from early, intermediate, and late stages of HIV infection.

Authors:  C Enger; N Graham; Y Peng; J S Chmiel; L A Kingsley; R Detels; A Muñoz
Journal:  JAMA       Date:  1996-05-01       Impact factor: 56.272

10.  The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1.

Authors:  J L Fahey; J M Taylor; R Detels; B Hofmann; R Melmed; P Nishanian; J V Giorgi
Journal:  N Engl J Med       Date:  1990-01-18       Impact factor: 91.245

View more
  1 in total

1.  Rapid dissemination of SIV follows multisite entry after rectal inoculation.

Authors:  Patricia Ribeiro Dos Santos; Magali Rancez; Jean-Luc Prétet; Alice Michel-Salzat; Valérie Messent; Anna Bogdanova; Anne Couëdel-Courteille; Evelyne Souil; Rémi Cheynier; Cécile Butor
Journal:  PLoS One       Date:  2011-05-09       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.